Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. Issue 8 (3rd July 2021)

• Record Type: Journal Article
• Authors: Rizzello, Ilaria; Cavo, Michele; Dozza, Luca; Rivolti, Elena; Petrucci, Maria Teresa; De Stefano, Valerio; Antonioli, Elisabetta; Tosi, Patrizia; D'Agostino, Mattia; Morè, Sonia; Gozzetti, Alessandro; Cea, Michele; Barbato, Simona; Tacchetti, Paola; Pantani, Lucia; Mancuso, Katia; Rocchi, Serena; De Cicco, Gabriella; Fusco, Alessio; Zamagni, Elena
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 8(2021)
• Page Start: 1897
• Page End: 1906
• Publication Date: 2021-07-03
• Subjects: Subcutaneous bortezomib -- multiple myeloma -- autologous transplantation -- peripheral neuropathy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1897805
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Subcutaneous (SC) bortezomib-based regimens represent the standard induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. Published data are based principally on intravenous (IV) administration: this retrospective observational study aimed to define patients' outcomes upon SC bortezomib administration, before and after ASCT. Of 131 enrolled patients, 86% received bortezomib-dexamethasone plus thalidomide (VTD), 5% plus cyclophosphamide (VCD), and 9% alone (VD), for a median of 4 cycles induction therapy, followed by single (52%) or double (48%) ASCT. 48 patients received consolidation with the same induction regimen. 35% had at least one adverse event, mainly gastrointestinal disorders and peripheral neuropathy (PN). ORR was 93.1%, 97.7% and 100%, after induction, ASCT(s) and consolidation, respectively. Median PFS and PFS2 were 55.8 months and 72 months, respectively, (median follow-up 45.3 months), while median OS was unreached. Concluding, SC bortezomib has similar efficacy with reduced PN than IV administration.